Bachem Holding Ag Class B · SIX:BANB
Bachem Holding Ag Class B — H1 2026 Earnings Presentation
24 slides from Bachem Holding Ag Class B's earnings presentation, Jul 30, 2026
Slide 1: Half-Year Results 2026
Half-Year Results 2026 A NNE -KA THRI N ST O LLER , A LA IN SC H A FFTER 30. JULY 2026 ZO O M CA LL
Slide 2: Housekeeping
Housekeeping At the end of the presentation there will be time for questions. Use the raise-your-hand -function during Q&A time. This call will be recorded, and the playback will be posted on Bachem.com. 2 Bachem HY Results 2026
Slide 3: Agenda
Agenda 1 Half-Year Results 2026 – Anne-Kathrin Stoller, CEO 2 Financial Review HY 2026 – Alain Schaffter, CFO 3 Outlook – Anne-Kathrin Stoller, CEO 4 Q & A - all 3 Bachem HY Results 2026
Slide 4: Half-Year Results 2026
HALF-YEAR RESULTS 2026 Anne-Kathrin Stoller, CEO 4 Bachem HY Results 2026
Slide 5: Management team built on strong experience
Management team built on strong experience Anne-Kathrin Stoller, CEO since 2026 • With Bachem since 2006 • Prior roles include the positions of COO Bachem Americas (’22-’25) and CCO (’18- 22’) Günther Loidl, CTO since 2015 Alain Schaffter, CFO since 2021 • With Bachem since 2000 • With Bachem since
Slide 6: Key results HY 2026
Key results HY 2026 CHF 326.4m CHF 82.8m CHF 148.4m Sales EBITDA CAPEX invested +4.3% 25.4% CHF 104.7m (in CHF) (EBITDA margin in CHF) Operating cash flow +7.3% 25.9% (in local currencies) (EBITDA margin in local currencies) Key driver: CMC -9.0% (in CHF) 2 725 Development. -4.2% (in local currencie
Slide 7: Sales HY 2026
Sales HY 2026 BACHEM WITH SOLID SALES GROWTH 4.3% 326.4 313.0 234.9 239.9 240.3 2022 2023 2024 2025 2026 Sales (in CHF million) 7 Bachem HY Results 2026
Slide 8: HY 2026 sales by product categories
HY 2026 sales by product categories Commercial API CMC Development Research & Specialties TOTAL (in CHF million) HY 2026 133.0 167.5 25.9 326.4 Change in CHF -21.0% +35.4% +23.4% +4.3% Change in local currency -19.3% +39.5% +30.5% +7.3% Sales share 40.7% 51.3% 7.9% 100% Rounding differences may occu
Slide 9: Capacity expansion
Capacity expansion Bubendorf Sisslerfeld United States • Building K: Production of • Signed agreement to supply • Investments in high-volume first commercial GMP large volumes of peptides capacity projects as well as material. as part of a strategic in modernization of small- • Existing campus: Seve
Slide 10: Financial Review HY 2026
FINANCIAL REVIEW HY 2026 Alain Schaffter, CFO 10 Bachem HY Results 2026
Slide 11: Key figures HY 2026
Key figures HY 2026 HY HY Change Change in 2026 2025 in CHF local currency Sales (in CHF million) 326.4 313.0 +4.3% +7.3% EBITDA (in CHF million) 82.8 91.0 -9.0% -4.2% in relation to sales 25.4% 29.1% EBIT (in CHF million) 54.1 66.9 -19.1% -13.1% in relation to sales 16.6% 21.4% Net income (in CHF m
Slide 12: Drivers of EBITDA margin (in %)
Drivers of EBITDA margin (in %) -370 bps 29.1 2.1 0.1 0.5 0.6 0.6 25.4 EBITDA COGS M&S R&D G&A / other Impact from EBITDA margin 2025 income currency margin 2026 In local currency, the EBITDA margin for 2026 is 25.9% 12 Bachem HY Results 2026
Slide 13: Cash flow analysis (in CHF million)
Cash flow analysis (in CHF million) +21.9 104.7 • Dividend paid -67.5 82.8 22.2 • Loans from banks +150.7 9.3 • Addition own shares -1.0 1.2 2.5 • Other items -0.2 80.9 86.2 20.6 166.2 0.1 82.0 EBITDA Income Other Change Change Change Change Operating Investing Financing Currency Net 2026 tax items
Slide 14: Balance sheet analysis (in CHF million)
Balance sheet analysis (in CHF million) Net liabilities Prepayments customers Balance sheet and equity ratio 455 2339 52 2109 31 369 142 895 -57 650 -26 182 -208 313 69% 62% 187 -157 Dec 31, 2025 June 30, 2026 Dec 31, 2025 June 30, 2026 Dec 31, 2025 June 30, 2026 Cash and cash equivalents Current pr
Slide 15: CAPEX overview 2022 – HY 2026 and outlook
CAPEX overview 2022 – HY 2026 and outlook 350 332.6 60 55 300 292.2 50 269.0 Outlook 2026: 45 250 CHF 350m to 40 CHF 400m 200 35 47.9% 30 142.6 48.3% 148.4 150 25 46.6% 20 100 45.5% 15 43.3 47.4 26.8% 37.4 10 50 28.6 5 33.3 0 0 2022 2023 2024 2025 HY 2026 CAPEX in CHF M Depreciation in CHF M CAPEX i
Slide 16: Outlook
OUTLOOK Anne-Kathrin Stoller, CEO 16 Bachem HY Results 2026
Slide 17: U.S. GLP-1 market to 2030: patient growth and API demand impact
U.S. GLP-1 market to 2030: patient growth and API demand impact • “Diabesity” is a massive U.S. health challenge o Nearly 90% of type 2 diabetes is linked to overweight and obesity. o >40% of U.S. adults live with obesity today (>100 million people). o Type 2 diabetes patients projected to grow from
Slide 18: Peptide market driven by metabolic launches
Peptide market driven by metabolic launches Growing Global Peptide Pipeline Phase 3 Peptide Projects by Indication 2026 already delivered four new peptide 16% therapeutic approvals, 196 188 185 184 178 175 highlighting the 160 commercial 151 149 149 3% 145 37% momentum of the 130 3% peptide sector.
Slide 19: Oligo market: towards larger indications
Oligo market: towards larger indications Growing Global Oligo Pipeline1 Phase 3 Oligo Projects by Indication2 Global pharma oligo 9% 18% portfolio with 132 ≈900 active 120 9% 115 projects. 98 95 94 80 75 ≈35% of the 72 12% 63 programs are 50 currently in 24% 38 clinical 28 24 24 24 development. 23 2
Slide 20: Business priorities 2026
Business priorities 2026 • Consistent, high-quality execution of existing contracts; customer satisfaction and patient supply. • Commercial production the first part of Building K while finishing the constructions of the second part. • Advance the Sisslerfeld project. • Prepare the ground for Bachem
Slide 21: 2026 outlook
2026 outlook 2026 35% - 40% growth in local currencies Sales (from 35% - 45%). EBITDA margin in low thirties in local Profitability currencies. 21 Bachem HY Results 2026
Slide 22: Thank you for your attendance
Thank you for your attendance Upcoming financial events Question? Send an e-mail to… Capital Markets Day November 26, 2026 ir@bachem.com Full-year 2026 report March 4, 2027 media@bachem.com Annual General Meeting April 28, 2027 22 Bachem HY Results 2026
Slide 23: Disclaimer
Disclaimer This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other
Slide 24: Thank you!
Thank you! bachem.com Bachem AG Bachem Americas, Inc. 4416 Bubendorf Torrance, CA 90505 Switzerland USA +41 585 95 20 21 +1 888 422 24 36 sales.ch@bachem.com sales.us@bachem.com 24 Bachem HY Results 2026